4-(methoxycarbonyl)phenyl boric acid | 460367-99-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(methoxycarbonyl)phenyl boric acid
• 英文别名: 4-(Methoxycarbonyl)phenylboric acid；(4-methoxycarbonylphenoxy)boronic acid
• CAS: 460367-99-1
• 化学式: C₈H₉BO₅
• 分子量: 195.967
• InChiKey: MKKWZXSLSSSUIY-UHFFFAOYSA-N

物化性质

• 沸点：
  351.6±44.0 °C(Predicted)
• 密度：
  1.291±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.18
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(methoxycarbonyl)phenyl boric acid 在 lithium hydroxide 、 四(三苯基膦)钯 作用下， 生成 4-(2-(8-chloro-4-methyl- 1,4-dihydroquinazolin-2-yl)thiazol-4-yl)benzoic acid
  参考文献：
  名称：

  EP3964509

  摘要：

  公开号：

文献信息

• NITROGEN-CONTAINING HETEROARYL COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：JAPAN TOBACCO INC.

  公开号：US20190152926A1

  公开（公告）日：2019-05-23

  The invention provides a compound having a GLUT9 inhibitory activity. The compound is of Formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

  该发明提供了一种具有GLUT9抑制活性的化合物。该化合物的化学式为[I]，其中每个符号如规范中所定义，或其药用可接受的盐。
• Synthesis and Antitumor Evaluation of Nitrovinyl Biphenyls: Anticancer Agents Based on Allocolchicines
  作者：Nishant Jain、Divya Yada、Thokhir B. Shaik、Galanki Vasantha、P. Surendra Reddy、Shasi V. Kalivendi、B. Sreedhar

  DOI：10.1002/cmdc.201100019

  日期：2011.5.2

  A new class of nitrovinyl biphenyl compounds based on the structures of colchicines and allocolchicines were designed, synthesized, and shown to inhibit tubulin polymerization and cause mitotic arrest. A majority of these compounds were found to possess potent anticancer properties, with IC50 values in the range of 0.05–7 μM, and are equally potent with colchicine in HeLa and MCF‐7 cells. Compounds

  设计，合成了基于秋水仙碱和二十碳五烯茶碱结构的新型一类硝基乙烯基联苯化合物，该化合物可抑制微管蛋白聚合并引起有丝分裂停滞。大多数这些化合物被发现具有有效的抗癌性质，带IC 50个中的0.05-7μ范围内的值中号，并且与在HeLa和MCF-7细胞秋水仙碱同等有效。化合物14e和14f抑制微管蛋白的组装超过60％，流式细胞仪研究表明，细胞周期的G 2 / M期细胞以浓度依赖的方式生长停滞。用14 f处理细胞导致细胞周期蛋白B1和极光激酶B mRNA水平的上调，这对应于细胞周期G 2 / M期的生长停滞（作为作用方式）。
• Compound
  申请人：Toda Ayako

  公开号：US20050261177A1

  公开（公告）日：2005-11-24

  This invention relates to new polypeptide compound represented by the following general formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

  本发明涉及一种由以下一般式（I）表示的新多肽化合物：其中R1、R2、R3、R4、R5和R6如描述中所定义或其盐，具有抗微生物活性（特别是抗真菌活性），抑制β-1,3-葡聚糖合酶的活性，制备其的方法，包含其的药物组合物，以及用于预防和/或治疗包括肺孢子虫感染（例如肺孢子虫肺炎）在内的人类或动物的传染病的方法。
• New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040242572A1

  公开（公告）日：2004-12-02

  The present invention relates to carboxamide compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 , R 2 , R 3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I1的羧酰胺化合物，其中A、B、W、X、Y、Z、R1、R2、R3和k的基团和残基具有权利要求1中所给出的含义。此外，本发明还涉及制备上述羧酰胺化合物的方法，以及含有本发明所述至少一种羧酰胺的制药组合物。基于它们的MCH受体拮抗活性，本发明的制药组合物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症、暴食症、厌食症、暴食症和糖尿病。
• EP3321256
  申请人：——

  公开号：——

  公开（公告）日：——